Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 2
2014 1
2015 3
2016 1
2018 2
2019 1
2020 3
2021 4
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Kurtz DM, et al. Among authors: alig s. Nat Biotechnol. 2021 Dec;39(12):1537-1547. doi: 10.1038/s41587-021-00981-w. Epub 2021 Jul 22. Nat Biotechnol. 2021. PMID: 34294911 Free PMC article.
Inferring gene expression from cell-free DNA fragmentation profiles.
Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, Steen CB, Macaulay CW, Schultz A, Nesselbush MC, Soo J, Schroers-Martin JG, Chen B, Binkley MS, Stehr H, Chabon JJ, Sworder BJ, Hui AB, Frank MJ, Moding EJ, Liu CL, Newman AM, Isbell JM, Rudin CM, Li BT, Kurtz DM, Diehn M, Alizadeh AA. Esfahani MS, et al. Among authors: alig sk. Nat Biotechnol. 2022 Apr;40(4):585-597. doi: 10.1038/s41587-022-01222-4. Epub 2022 Mar 31. Nat Biotechnol. 2022. PMID: 35361996 Free PMC article.
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Shahrokh Esfahani M, Nabet BY, Soo J, Scherer F, Craig AFM, Casasnovas O, Westin JR, Gaidano G, Rossi D, Roschewski M, Wilson WH, Meignan M, Diehn M, Alizadeh AA. Alig S, et al. J Clin Oncol. 2021 Aug 10;39(23):2605-2616. doi: 10.1200/JCO.20.02573. Epub 2021 Apr 28. J Clin Oncol. 2021. PMID: 33909455 Free PMC article.
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.
Bararia D, Hildebrand JA, Stolz S, Haebe S, Alig S, Trevisani CP, Osorio-Barrios F, Bartoschek MD, Mentz M, Pastore A, Gaitzsch E, Heide M, Jurinovic V, Rautter K, Gunawardana J, Sabdia MB, Szczepanowski M, Richter J, Klapper W, Louissaint A Jr, Ludwig C, Bultmann S, Leonhardt H, Eustermann S, Hopfner KP, Hiddemann W, von Bergwelt-Baildon M, Steidl C, Kridel R, Tobin JWD, Gandhi MK, Weinstock DM, Schmidt-Supprian M, Sárosi MB, Rudelius M, Passerini V, Mautner J, Weigert O. Bararia D, et al. Among authors: alig s. Cell Rep. 2020 May 5;31(5):107522. doi: 10.1016/j.celrep.2020.107522. Epub 2020 Apr 23. Cell Rep. 2020. PMID: 32330423 Free article.
Molecular Monitoring of Lymphomas.
Schroers-Martin JG, Alig S, Garofalo A, Tessoulin B, Sugio T, Alizadeh AA. Schroers-Martin JG, et al. Among authors: alig s. Annu Rev Pathol. 2022 Sep 21. doi: 10.1146/annurev-pathol-050520-044652. Online ahead of print. Annu Rev Pathol. 2022. PMID: 36130071 Review.
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L, Kruger S, Heinemann V, Bararia D, Haebe S, Alig S, Haas M, Zhang D, Westphalen CB, Ormanns S, Metzger P, Werner J, Weigert O, von Bergwelt-Baildon M, Rataj F, Kobold S, Boeck S. Sams L, et al. Among authors: alig s. Clin Transl Oncol. 2021 Nov;23(11):2394-2401. doi: 10.1007/s12094-021-02620-x. Epub 2021 Apr 19. Clin Transl Oncol. 2021. PMID: 33876417 Free PMC article.
Impact of age on clinical risk scores in follicular lymphoma.
Alig S, Jurinovic V, Pastore A, Haebe S, Schmidt C, Zoellner AK, Dreyling M, Unterhalt M, Hoster E, Hiddemann W, Weigert O. Alig S, et al. Blood Adv. 2019 Apr 9;3(7):1033-1038. doi: 10.1182/bloodadvances.2019032136. Blood Adv. 2019. PMID: 30940638 Free PMC article.
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR. Mondello P, et al. Among authors: alig s. Cancer Discov. 2020 Mar;10(3):440-459. doi: 10.1158/2159-8290.CD-19-0116. Epub 2020 Jan 8. Cancer Discov. 2020. PMID: 31915197 Free PMC article.
Impact of age on genetics and treatment efficacy in follicular lymphoma.
Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner AK, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O. Alig S, et al. Haematologica. 2018 Aug;103(8):e364-e367. doi: 10.3324/haematol.2018.187773. Epub 2018 Mar 15. Haematologica. 2018. PMID: 29545350 Free PMC article. No abstract available.
Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
Alig S, Jurinovic V, Shahrokh Esfahani M, Haebe S, Passerini V, Hellmuth JC, Gaitzsch E, Keay W, Tahiri N, Zoellner A, Rosenwald A, Klapper W, Stein H, Feller A, Ott G, Staiger AM, Horn H, Hansmann ML, Pott C, Unterhalt M, Schmidt C, Dreyling M, Alizadeh AA, Hiddemann W, Hoster E, Weigert O. Alig S, et al. Blood Adv. 2020 Sep 22;4(18):4451-4462. doi: 10.1182/bloodadvances.2020002546. Blood Adv. 2020. PMID: 32941649 Free PMC article. Clinical Trial.
18 results